Anti-mouse CD4-InVivo is an anti-mouse CD4 antibody inhibitor that can be used in related research in the field of life sciences. Its product number is T35388.

Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody that targets the CD4 molecule and effectively inhibits T-cell receptor (TCR) signal transduction. It is used in the research of rheumatoid arthritis, psoriasis, melanoma, cutaneous, and peripheral T-cell lymphoma [1].

The Anti-Mouse CD44 Antibody is a rat-derived IgG2b inhibitor targeting mouse CD44.

Semzuvolimab, a murine IgG1κ antibody, targets the p55 T-cell surface antigen T4/Leu-3 (CD4). It has demonstrated capabilities to neutralize HIV infection and may inhibit HIV in patients on stable highly active antiretroviral therapy (HAART) [1] [2].

Priliximab (CEN 000029), an anti-CD4 humanized monoclonal antibody, binds to CD4 receptors on T cells, leading to a significant and sustained decrease in circulating CD4+ T cells. This property renders it useful in the study of rheumatoid arthritis (RA) [1].

Cedelizumab (RWJ 49004), an IgG4 monoclonal antibody, selectively targets CD4 and exhibits immunosuppressant properties [1].

Clenoliximab (IDEC-151), a macaque-human chimeric monoclonal antibody (immunoglobulin G4), targets the CD4 molecule on T lymphocytes' surface and is utilized in rheumatoid arthritis research [1].

Efineptakin alfa (NT-17), a long-acting recombinant human interleukin-7 (IL-7), promotes the proliferation and survival of CD4+ and CD8+ cells in both humans and mice. It has applications in glioblastoma research [1].

Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.Ibalizumab has anti-HIV-1 infectious activity and may be used to maintain normal immune function.

Alvircept sudotox, a recombinant CD4 fused with exotoxin A from Pneumonas aeruginosa, is utilized in HIV infection research [1].

Ivuxolimab, an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody, targets a costimulatory receptor found on activated CD4+ and CD8+ T cells. It demonstrates antitumor properties and may exhibit immunostimulatory activity [1].

Tregalizumab, a humanized IgG1-type monoclonal antibody targeting CD4, selectively activates regulatory T cells (Tregs) with suppressive functions in vitro and has potential applications in researching autoimmune diseases (due to inadequate Treg activity) and allergies [1] [2] [3].

Keliximab (SB-210396), a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody, demonstrates a binding affinity for soluble CD4 with a K i value of 1.0 nM. It inhibits T cell proliferation and IL-2 production, making it a valuable agent for cancer research [1] [2].